Related Experiment Videos
[Clinical studies on SY5555 in the field of pediatrics]
1Department of Pediatrics, Anjo Kosei Hospital.
Insights
This study evaluated SY5555 dry syrup, a new oral penem antibiotic, in pediatric patients. The antibiotic demonstrated high clinical efficacy with minimal side effects in children with bacterial infections.
Area of Science:
- Pediatric infectious diseases
- Antibiotic therapy
- Pharmacology
Background:
- Bacterial infections pose a significant health risk in children.
- Novel antibiotics are needed to combat evolving resistance patterns.
- Penem antibiotics offer broad-spectrum activity against various pathogens.
Purpose of the Study:
- To assess the clinical efficacy and safety of SY5555 dry syrup.
- To evaluate SY5555 in treating common pediatric bacterial infections.
- To determine the tolerability profile of SY5555 in a pediatric population.
Main Methods:
- Clinical trials were conducted on pediatric patients.
- SY5555 dry syrup was administered orally.
- Patients presented with diverse bacterial infections including acute tonsillitis, bronchitis, pharyngitis, scarlet fever, pertussis, and urinary tract infections.
Main Results:
- SY5555 demonstrated a 90% overall clinical efficacy rate.
- The antibiotic was administered to 10 children with various bacterial infections.
- Adverse events were minimal, with only one case each of loose stool and eosinophilia observed.
Conclusions:
- SY5555 dry syrup is a highly effective antibiotic for pediatric bacterial infections.
- The safety profile of SY5555 is favorable, with low incidence of side effects.
- SY5555 represents a promising new treatment option in pediatric infectious disease management.
Abstract:
Clinical studies on SY5555 dry syrup, a new oral penem antibiotic, were carried out in the field of pediatrics. The following results were obtained. 1. SY5555 was administered to 10 children with various bacterial infections (2 patients with acute tonsillitis, 2 with acute bronchitis, 1 with pharyngitis, 2 with scarlet fever, 1 with pertussis and 2 with urinary tract infections). The overall clinical efficacy rate was 90%. 2. Side effects or abnormal laboratory test values were not observed except for loose stool in 1 and eosinophilia in 1.